Comparative Pharmacology
Head-to-head clinical analysis: OXILAN 300 versus RENO 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXILAN 300 versus RENO 30.
OXILAN-300 vs RENO-30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that attenuates X-rays and enhances vascular and tissue visualization during imaging procedures.
Iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during radiographic procedures.
Intravenous: 1-2 mL/kg (300 mg iodine/mL) for contrast imaging; maximum dose 2 mL/kg per procedure.
Adults: 30 mL (30 g iodine) intravenously as a single dose for imaging procedures; may repeat once if needed.
None Documented
None Documented
Terminal half-life: 1.5–2.5 hours (normal renal function); prolonged in renal impairment (up to 30 hours in severe impairment).
Terminal half-life: 1-2 hours (normal renal function); prolonged to 20-40 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Renal elimination: 100% unchanged via glomerular filtration; biliary/fecal excretion negligible (<1%).
Renal: >95% unchanged via glomerular filtration; biliary/fecal: <5%.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent